Saituo (trastuzumab biosimilar) / Sino Biopharm, Shenzhen Kexing Pharma - LARVOL DELTA

Trastuzumab (Certol) for Injection of Sino Biopharmaceuticals Approved for Marketing (Sino Biopharm Press Release) - "...the trastuzumab biosimilar drug for injection (trade name: Xerto) developed and produced by Chia Tai Tianqing, a subsidiary of China Biopharmaceuticals, was officially approved and issued by the National Medical Products Administration (NMPA). Certificate', approved for the treatment of HER2 positive early breast cancer, metastatic breast cancer and metastatic gastric cancer....The approval of Cyto (trastuzumab for injection) is based on the efficacy, safety and efficacy of TQ-B211 combined with docetaxel and Herceptin combined with docetaxel in the first-line treatment of patients with HER2-positive metastatic breast cancer. Double-blind, randomized, multicenter, phase III clinical study of immunogenicity."

Non-US regulatory • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Kexing Biopharm Obtains the Products of Trastuzumab and Neratinib Maleate Tablets (Yahoo Finance) - "Recently, Kexing Biopharm...signed with Chia-Tai Tianqing (CTTQ) an exclusive cooperation agreement for overseas commercialization of Trastuzumab for Injection. As a result, it has obtained the rights to commercialize the first batch of Trastuzumab for Injection in 12 countries. Meanwhile, Kexing has also signed with Convalife Pharmaceuticals a cooperation agreement for the international commercialization of Neratinib Maleate Tablets. Kexing Biopharm has obtained the rights to commercialize Convalife Pharmaceuticals' Neratinib Maleate Tablets in six countries, including Indonesia, Thailand, Vietnam, the Philippines, Malaysia, and Egypt. These agreements not only further expand the pipeline of Kexing Biopharm's antitumor products, but also showcase its strength in overseas commercialization. CTTQ's Trastuzumab biosimilar has been applied for marketing in China for treatment of metastatic breast cancer, early stage breast cancer, and metastatic gastric cancer."

Licensing / partnership • Non-US regulatory • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor